Trial
NCT03988582
Safety and Effectiveness of EBV-specific Cytotoxic T Cells for the Treatment for EBV Lymphomas or Other EBV-associated Malignancies
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Memorial Sloan Kettering Cancer Center
Collaborators
—
Condition
EBV Lymphomas
Intervention
EBV-specific T-cells
Why stopped
Lack of accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-06-11